Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous
case reports and retrospective data. This study compares cyclosporin versus rituximab in
steroid-refractory anemia.